Alteration of BIRC3 and multiple other NF-κB pathway genes in splenic marginal zone lymphoma

Blood

Volumn 118, Issue 18, 2011, Pages 4930-4934

  Rossi, Davide ^a   Deaglio, Silvia ^b   Dominguez Sola, David ^c   Rasi, Silvia ^a   Vaisitti, Tiziana ^b   Agostinelli, Claudio ^d   Spina, Valeria ^a   Bruscaggin, Alessio ^a   Monti, Sara ^a   Cerri, Michaela ^a   Cresta, Stefania ^a   Fangazio, Marco ^a   Arcaini, Luca ^e   Lucioni, Marco ^e   Marasca, Roberto ^f   Thieblemont, Catherine ^g   Capello, Daniela ^a   Facchetti, Fabio ^h   Kwee, Ivo ⁱ   Pileri, Stefano A ^d   Foà, Robin ^j   Bertoni, Francesco ⁱ   Dalla Favera, Riccardo ^c,k   Pasqualucci, Laura ^c,k,l   Gaidano, Gianluca ^a   more..

^a UNIVERSITY OF EASTERN PIEDMONT   (Italy)

^b UNIVERSITY OF TURIN   (Italy)

^c Och Spine at New York Presbyterian Hospitals   (United States)

^d UNIVERSITY OF BOLOGNA   (Italy)

^e UNIVERSITY OF PAVIA   (Italy)

^f UNIVERSITY OF MODENA AND REGGIO EMILIA   (Italy)

^g SAINT LOUIS HOSPITAL   (France)

^h SPEDALI CIVILI   (Italy)

ⁱ ONCOLOGY INSTITUTE OF SOUTHERN SWITZERLAND   (Switzerland)

^j SAPIENZA UNIVERSITY OF ROME   (Italy)

^k NewYork Presbyterian Hospital   (United States)

^l UNIVERSITY OF PERUGIA   (Italy)

more..

Author keywords

[No Author keywords available]

Indexed keywords

IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; MITOGEN ACTIVATED PROTEIN KINASE KINASE KINASE; TUMOR NECROSIS FACTOR RECEPTOR ASSOCIATED FACTOR 3;

ARTICLE; BIRC3 GENE; CONTROLLED STUDY; COPY NUMBER VARIATION; GENE; GENE INACTIVATION; GENE MUTATION; HUMAN; HUMAN CELL; HUMAN TISSUE; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; RING FINGER MOTIF; SOMATIC MUTATION; SPLENIC MARGINAL ZONE LYMPHOMA; TRANSLOCATION LINE;

EID: 80855133512     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2011-06-359166     Document Type: Article

References (25)

1. Isaacson PG, Piris MA, Berger F, et al. Splenic marginal zone lymphoma. In: Swerdlow SH, Campo E, Harris NL, et al., eds. WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues. Lyon, France: IARC; 2008:185-187.
2. Matutes E, Oscier D, Montalban C, et al. Splenic marginal zone lymphoma proposals for a revision of diagnostic, staging and therapeutic criteria. Leukemia. 2008;22(3):487-495. (Pubitemid 351386718)
3. Salido M, Baró C, Oscier D, et al. Cytogenetic aberrations and their prognostic value in a series of 330 splenic marginal zone B-cell lymphomas: a multicenter study of the Splenic B-Cell Lymphoma Group. Blood. 2010;116(9):1479-1488.
4. Zibellini S, Capello D, Forconi F, et al. Stereotyped patterns of B-cell receptor in splenic marginal zone lymphoma. Haematologica. 2010; 95(10):1792-1796.
5. Rinaldi A, Mian M, Chigrinova E, et al. Genomewide DNA profiling of marginal zone lymphomas identifies subtype-specific lesions with an impact on the clinical outcome. Blood. 2011;117(5):1595- 1604.
6. Xie P, Stunz LL, Larison KD, Yang B, Bishop GA. Tumor necrosis factor receptor-associated factor 3 is a critical regulator of B cell homeostasis in secondary lymphoid organs. Immunity. 2007; 27(2):253-267. (Pubitemid 47284931)
7. Sasaki Y, Calado DP, Derudder E, et al. NIK overexpression amplifies, whereas ablation of its TRAF3-binding domain replaces BAFF:BAFF-Rmediated survival signals in B cells. Proc Natl Acad Sci U S A. 2008;105(31):10883-10888.
8. Conze DB, Zhao Y, Ashwell JD. Non-canonical NF-kappaB activation and abnormal B cell accumulation in mice expressing ubiquitin protein ligase- inactive c-IAP2. PLoS Biol. 2010;8(10): e1000518.
9. Ruiz-Ballesteros E, Mollejo M, Rodriguez A, et al. Splenic marginal zone lymphoma: proposal of new diagnostic and prognostic markers identified after tissue and cDNA microarray analysis. Blood. 2005;106(5):1831-1838. (Pubitemid 41208601)
10. Compagno M, Lim WK, Grunn A, et al. Mutations of multiple genes cause deregulation of NFkappaB in diffuse large B-cell lymphoma. Nature. 2009;459(7247):717-721.
11. Staudt LM. Oncogenic activation of NF-kappaB. Cold Spring Harb Perspect Biol. 2010;2(6): a000109.
12. Vallabhapurapu S, Karin M. Regulation and function of NF-kappaB transcription factors in the immune system. Annu Rev Immunol. 2009;27:693- 733.
13. Vallabhapurapu S, Matsuzawa A, Zhang W, et al. Nonredundant and complementary functions of TRAF2 and TRAF3 in a ubiquitination cascade that activates NIK-dependent alternative NFkappaB signaling. Nat Immunol. 2008;9(12): 1364-1370.
14. Zarnegar BJ, Wang Y, Mahoney DJ, et al. Noncanonical NF-kappaB activation requires coordinated assembly of a regulatory complex of the adaptors cIAP1, cIAP2, TRAF2 and TRAF3 and the kinase NIK. Nat Immunol. 2008;9(12):1371- 1378.
15. Dierlamm J, Baens M, Wlodarska I, et al. The apoptosis inhibitor gene API2 and a novel 18q gene, MLT, are recurrently rearranged in the t(11; 18)(q21;q21) associated with mucosa-associated lymphoid tissue lymphomas. Blood. 1999;93(11): 3601-3609. (Pubitemid 29249804)
16. Li X, Yang Y, Ashwell JD. TNF-RII and c-IAP1 mediate ubiquitination and degradation of TRAF2. Nature. 2002;416(6878):345-347.
17. Hu S, Du MQ, Park SM, et al. cIAP2 is a ubiquitin protein ligase for BCL10 and is dysregulated in mucosa-associated lymphoid tissue lymphomas. J Clin Invest. 2006;116(1):174-181. (Pubitemid 43121802)
18. He JQ, Saha SK, Kang JR, Zarnegar B, Cheng G. Specificity of TRAF3 in its negative regulation of the noncanonical NF-kappa B pathway. J Biol Chem. 2007;282(6):3688-3694. (Pubitemid 47084476)
19. He L, Grammer AC, Wu X, Lipsky PE. TRAF3 forms heterotrimers with TRAF2 and modulates its ability to mediate NF-kappaB activation. J Biol Chem. 2004;279(53):55855-55865. (Pubitemid 40066593)
20. Annunziata CM, Davis RE, Demchenko Y, et al. Frequent engagement of the classical and alternative NF-kappaB pathways by diverse genetic abnormalities in multiple myeloma. Cancer Cell. 2007;12(2):115-130. (Pubitemid 47199123)
21. Keats JJ, Fonseca R, Chesi M, et al. Promiscuous mutations activate the noncanonical NFkappaB pathway in multiple myeloma. Cancer Cell. 2007;12(2):131-144. (Pubitemid 47208626)
22. Novak U, Rinaldi A, Kwee I, et al. The NF-κB negative regulator TNFAIP3 (A20) is inactivated by somatic mutations and genomic deletions in marginal zone lymphomas. Blood. 2009;113(20): 4918-4921.
23. Braggio E, Keats JJ, Leleu X, et al. Identification of copy number abnormalities and inactivating mutations in two negative regulators of nuclear factor-kappaB signaling pathways in Waldenstrom's macroglobulinemia. Cancer Res. 2009; 69(8):3579-3588.
24. Mercurio F, Zhu H, Murray BW, et al. IKK-1 and IKK-2: cytokine-activated IkappaB kinases essential for NF-kappaB activation. Science. 1997; 278(5339):860-866. (Pubitemid 27467923)
25. Calado DP, Zhang B, Srinivasan L, et al. Constitutive canonical NF-kappaB activation cooperates with disruption of BLIMP1 in the pathogenesis of activated B cell-like diffuse large cell lymphoma. Cancer Cell. 2010;18(6):580-589.